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Abstract
Background: In Australia, HIV is concentrated in men who have sex with men (MSM) and rates have increased
steadily over the past ten years. Health promotion strategies should ideally be informed by an understanding of
both the prevalence of the factors being modified, as well as the size of the risk that they confer. We undertook an
analysis of the potential population impact and cost saving that would likely result from modifying key HIV risk
factors among men who have sex with men (MSM) in Sydney, Australia.
Methods: Proportional hazard analyses were used to examine the association between sexual behaviours in the last six
months and sexually transmissible infections on HIV incidence in a cohort of 1426 HIV-negative MSM who were recruited
primarily from community-based sources between 2001 and 2004 and followed to mid-2007. We then estimated the
proportion of HIV infections that would be prevented if specific factors were no longer present in the population, using a
population attributable risk (PAR) method which controls for confounding among factors. We also calculated the average
lifetime healthcare costs incurred by the HIV infections associated with specific factors by estimating costs associated
with clinical care and treatment following infection and discounting at 3% (1% and 5% sensitivity) to present value.
Results: Unprotected anal intercourse (UAI) with a known HIV-positive partner was reported by 5% of men, the
hazard ratio (HR) was 16.1 (95%CI:6.4-40.5), the PAR was 34% (95%CI:24-44%) and the average lifetime HIV-related
healthcare costs attributable to UAI with HIV-positive partners were $AUD102 million (uncertainty range: $93-114 m).
UAI with unknown HIV status partners was reported by 25% of men, the HR was 4.4 (95%CI:1.8-11.2), the PAR was
33% (95%CI:26-42%) and the lifetime incurred costs were $AUD99 million. Anal warts prevalence was 4%, the HR was
5.2 (95%CI:2.4-11.2), the PAR was 13% (95%CI:9-19%) and the lifetime incurred costs were $AUD39 million.
Conclusions: Our analysis has found that although UAI with an HIV-positive sexual partner is a relatively low-
prevalence behaviour (reported by 5% of men), if this behaviour was not present in the population, the number of
infections would be reduced by one third. No other single behaviour or sexually transmissible infections
contributes to a greater proportion of infections and HIV-related healthcare costs.
Background
In Australia, there were 1050 new cases of HIV diag-
nosed in 2009, bringing the estimated number of people
living with HIV infection by the end of that year to
20,171 [1]. HIV has been highly concentrated among
men who have sex with men (MSM) since the epidemic
began nearly 30 years ago. After a long decline, rates of
HIV diagnosis in MSM began increasing ten years ago
and have continued to do so, almost certainly reflecting
a resurgence in incidence of infection [2]. Unprotected
anal intercourse (UAI) has been identified as the main
mode of HIV acquisition in Australia [3,4] and the fre-
quency of this behaviour has increased steadily since the
mid-1990s [5,6].
The broad category of UAI in fact represents a spec-
trum of behaviours, which have documented different
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being associated with different levels of risk. This per-
ception has led HIV-negative men wishing to engage in
UAI to adopt behaviours that they believe reduce their
risk of infection, including choosing partners perceived
to be HIV-negative (“serosorting”) ,f o r m i n gl o n gt e r m
relationships involving explicit sexual agreements with
partners who are HIV-negative (‘negotiated safety), per-
forming insertive anal intercourse only (“strategic posi-
tioning”) and avoidance of ejaculation inside the rectum
as the receptive partner (“withdrawal”) [8].
Health promotion strategies for MSM have also recog-
nised the need to make distinctions among these differ-
ent subcategories of UAI, but have been complicated by
ongoing debates as to which, if any of the modes can be
recommended as “safer”, let alone “safe”. Until recently,
there has also been a relative absence of quantitative
data on the risk associated with the various forms of
UAI, so that it has been difficult to undertake health
promotion that is truly evidence based. Furthermore,
biomedical prevention strategies such as circumcision
and STI treatment are on the prevention agenda, with-
out a comprehensive assessment of what population
impact they could potentially achieve. In Australia, cir-
cumcision has been associated with a significant reduc-
tion in HIV incidence among those MSM who reported
a preference for the insertive role in anal intercourse
[9]. The early detection and treatment of curable anal
and urethral sexually transmitted infections (STIs) has
been suggested as a possible strategy for HIV prevention
in MSM [10] based on observational studies demon-
strating independent associations between HIV serocon-
verison and prior STIs in MSM [11,12].
Analyses of data from a large cohort of gay men has
gone some way towards filling this gap in the evidence
base for risk factors, by estimating the relative risk of
HIV acquisition associated with specific subcategories of
UAI, and other prevention related factors such as STI
control and circumcision [8].
In this paper, we take this analysis further, through
the use of the population attributable risk (PAR), which
takes account of both the relative risk (RR) of specific
risk factors, and their prevalence in the population. The
PAR provides a quantitative assessment of the potential
impact of risk factor on disease incidence in the popula-
tion [13]. Instead of using the traditional method of cal-
culating PAR, we use a more comprehensive PAR
method described by Spiegelman (2007) [13] and Wand
(2009) [14] which adjusts for the effects of other vari-
ables. The only PAR papers previously published in this
field did not use this adjustment [15-17]. We also exam-
ine the estimated savings in HIV-related health care
costs associated with each risk factor by estimating
subsequent costs associated with clinical care and man-
agement of HIV infection.
Methods
Study Population
The study population consisted of men participating in
the Health in Men (HIM) study, which was a prospec-
tive cohort of MSM in Sydney, Australia. HIV-negative
men (n = 1426) who were non-randomly recruited pri-
marily from community-based sources between 2001
and 2004 and followed to mid-2007 [8,18]. Participants
underwent annual HIV testing, and detailed information
on sexual risk behaviour was collected every 6 months.
Sexual risk behaviours
We adopted definitions of sexual behaviours and partner
choice strategies as in the earlier analysis by Jin and col-
leagues [8] and included strategic positioning, withdra-
wal and serosorting, as defined above. The definitions of
risk reduction behaviours were based on exclusive prac-
tice. For example, if a man reported insertive UAI and
any receptive UAI during a 6-month period, he was
classified as not reporting strategic positioning in the
period. The extent of practising each behaviour was
quantified for all men at each six monthly cohort study
interview.
We did not include substance use as a category in the
model, as drugs used specifically to enhance sexual plea-
sure, particularly oral erectile dysfunction medications,
have been associated with increased sexual risk beha-
viour, but are not direct risk factors for HIV transmis-
sion [19] and injecting drug use is not a major risk for
HIV transmission in MSM in Australia [1].
Circumcision
We included circumcision status as described in a paper
by Templeton and colleagues [9]. Circumcision status
was reported at baseline and self-reported circumcision
status was validated by clinical examination in a sub-
group of 240 consecutively presenting participants [20].
STIs
We also included specific STIs in the PAR analysis
selected on the basis of being found to be associated
with a significant increased risk of HIV seroconversion
in an earlier analysis by Jin and colleagues which
adjusted for sexual risk behaviour [21]. These STIs
included self-reported anal warts between cohort study
visits and anal gonorrhoea at the cohort study visit.
Infectious syphilis and herpes simplex virus 2 (HSV2)
were not found to be significantly associated with HIV
seroconversion in this analysis and were not included in
our PAR regression model.
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For HIV incidence, total person-years were calculated as
the time from study entry to the estimated date of sero-
conversion, or to the end of the study in June 2007 for
those who remained HIV-negative. The midpoint
between interviews was used as the date of infection for
participants who had an interval or study‐visit diagnosis.
Identifiers were matched against the Australian national
HIV register each year to identify infections which
occurred in those who tested outside the study or had
been lost to active follow-up.
Population attributable risk
We adapted the method described by Spiegelman (2007)
[13] and Wand (2009) [14] to estimate the PAR. PAR
quantifies the potential impact of risk factor on disease
incidence in the population. The PAR is calculated
based on the RR or hazard ratio HR of the association
between the risk factor (sexual behaviour or STI) and
the outcome (HIV incidence), combined with the preva-
lence of the risk factor.
Specifically, the PARs were calculated as follows. When
there is only one risk factor, at two levels (1 versus 0)
PAR =
p(HR − 1)
p(HR − 1) + 1
=1−
1
2
s=1 psHRs
(1)
Where HR is the hazard ratio, p is the prevalence of
the risk factor in the population and s indexes the two
strata determined by the value of the risk factor. Equa-
tion 1 can be generalized to the multi-factorial setting
when there are more than one risk factors at multiple
levels, as
PAR =
S
s=1 ps(HRs − 1)
1+
S
s=1 ps(HRs − 1)
=1−
1
2
s=1 psHRs
(2)
Where HRs and ps, s =1 , . . . S, are the hazard ratios and
the prevalences in the target population for the s th
combination of the risk factors. Full PAR can be esti-
mated by using Equation 2 and interpreted as the per-
cent reduction expected in the number of HIV
seroconversion if all the known risk factors were elimi-
nated from the target population.
In a multifactorial disease setting, at least some key
risk factors such as age and sex are not modifiable. This
limits the practical utility of the full PAR which is based
on modification of all variables of interests. In an eva-
luation of a preventive intervention in a multifactorial
disease setting, the interest is in the percent of cases
associated with the exposures to be modified, when
other risk factors, particularly non-modifiable ones are
present but do not change as a result of the interven-
tion. Therefore we derived and used partial PAR,
assuming that the unmodifiable variable(s) remained
unchanged.
Under the assumption of no interaction between the
modifiable and non-modifiable risk factors of interest,
the partial PAR is formulated as
PAR =
S
s=1
T
t=1 pstHR1sHR2t −
S
s=1
T
t=1 pstHR2t
S
s=1
T
t−1 pstHR1sHR2t
=1−
T
t=1 ptHR2t
S
s=1
T
t=1 pstHR1sHR2t (3)
where t denotes a stratum of unique combinations of
levels of all background risk factors which are not modi-
fiable and/or not under study, t = 1,...,T and HR2t is the
hazard ratio in combination t relative to the lowest risk
level, where HR2,1 =1 .A sp r e v i o u s l y ,s indicates a risk
factor defined by each of the unique combinations of
the levels of the modifiable risk factors, that is, those
risk factors to which the PAR applies, s = 1,...,S,a n d
HR1s is the relative risk corresponding to combinations
relative to the lowest risk combination, HR1,1 =1 .T h e
joint prevalence of exposure group s and stratum t is
denoted by pst,a n dp.t =
S
s=1 pst.T h eP A Rr e p r e s e n t s
the difference between the number of cases expected in
the original cohort and the number of cases expected if
all subsets of the cohort who were originally exposed to
the modifiable risk factor(s) had eliminated their expo-
sure(s) so that their relative risk compared to the unex-
posed was 1, divided by the number of cases expected
in the original cohort.
The HR for each of the sexual behaviours were deter-
mined using a Cox regression model. The prevalence of
the behaviours were time dependent, taking account of
behaviour each six months during the cohort. In our
study, a univariate PAR analysis was undertaken, followed
by a multivariate analysis which adjusts for the effects of
other variables and assumes non-modifiable risk factors
are unchanged. The PAR represents an estimate of the
proportion of infections eliminated, taking account of rela-
tionships with other variables. We established two models.
Model 1 included all factors with sexual behaviour broken
down according to HIV status of the sexual partner.
Model 2 included all factors with sexual behaviour broken
down according to the sexual position. We were unable to
include both sexual position and partner’s serostatus in
the same model because of the sparse data which led to
empty cells in the combination levels.
95% CIs were estimated for individual risk factors
using SAS statistical software, version 9 [22].
HIV costs
We estimated the average lifetime healthcare costs asso-
ciated with each HIV infection (over 40 years post-infec-
tion), factoring the expected delays between infection and
clinical care, including initiation of antiretroviral therapy,
and discounting all costs to 2010 Australian dollars.
Firstly, we estimated the average time from infection to
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nosed with HIV in Australia have a CD4 count less than
200 cells per μl and a further 20% have a CD4 count
between 200 and 350 cells per μl; the time between infec-
tion and diagnosis is assumed to be 10 years (uncertainty
range: 8-12 years) and 7 years (4-8.5 years), respectively,
based on average rates of CD4 decline (e.g. see [23]). This
40% of HIV-infected people are assumed to initiate ther-
apy at the time of HIV diagnosis. A further 20% of HIV
diagnoses in Australia have a CD4 count between 350 and
500 cells per μl at diagnosis and it is assumed that they
have been infected for ~4 years and they will remain off
antiretroviral medications for a further 2 (0-4) years. The
remaining 40% of HIV diagnoses in Australia have a CD4
count greater than 500 cells per μla td i a g n o s i sa n di ti s
assumed that they have been infected for ~1.5 years on
average and they will remain off antiretroviral medications
for a further 4.5 (2.5-6.5) years (half of this time with CD4
count greater than 500). The average annual healthcare
costs for people living with diagnosed HIV but not yet
receiving antiretroviral therapy is estimated to be AUD
$1523 for people with a CD4 count greater than 500 and
AUD$2055 for people with a CD4 count between 350 and
500, as published in the Australian 2009 Return on Invest-
ment 2 (ROI2) Report [24]. As previously estimated [24],
standard first-line antiretroviral therapies in Australia cost
AUD$14,613 per year, second-line therapies cost AUD
$15,178 per year and third- and subsequent lines of ther-
apy cost an average of AUD$27,776 per year. There is an
estimated AUD$2731 in additional annual healthcare costs
for people on therapy, associated with CD4 and viral load
tests, general and specialist consultations, hospitalisations
etc [24]. Based on antiretroviral pathway data from the
clinic-based Australian HIV Observational Database
(AHOD) [25], the mean average duration remaining on
first-line regimens in Australia before switching to a sec-
ond-line therapy is 5.0 years, and the average durations
remaining on second- and subsequent-line of therapies are
5.8 years and 4.4 years, respectively. These assumptions
around time delays between infection and initiating clini-
cal care and treatment, when healthcare costs become
relevant, are presented in Figure 1. We calculated lifetime
costs associated with HIV infection, assumed to be over
40 years from the time of infection, discounting costs at a
rate of 3% per year with sensitivity analyses of 1% and 5%.
Accordingly, the estimated average lifetime HIV-related
healthcare costs are AUD$429,662 ($391,107-477,626) for
3% discounting, and AUD$681,381 ($632,453-739,807)
and AUD$282,267 ($251,419-322,219) for 1% and 5% dis-
counting, respectively.
In recent years the numbers of HIV diagnoses in
Australia have remained relatively stable at approxi-
mately 1000 cases diagnosed per year (annual average
of 1027 over the past four years). Of these cases,
70.05% (~700 per year) were associated with men who
reported sex with another men as the risk exposure
[1]. To calculate the average healthcare costs incurred
from HIV seroconversions associated with specific risk
factors, we multiplied the PAR percent for each speci-
fic risk factor, by the 700 HIV infections associated
with male homosexual exposure, by the average health-
care costs per HIV-infected person. We performed
sensitivity analyses by rate of discounting and accord-
ing to the bounds in delays in durations of time
between infection and diagnoses and commencement
of antiretroviral treatment but calculations were based
on the best estimated PAR of the risk factors and not
the 95% CI of the PAR.
Results
Prevalence of risk factors
Table 1 provides the frequency distributions of sexual
behaviours and select STIs reported in the HIM study
considered in this study.
UAI by reported HIV status of sexual partners
A third of men (33%) reported UAI with HIV-negative
partners only, a quarter (25%) reported UAI with men of
unknown status and 5% reported UAI with HIV-positive
men.
UAI by sexual position
A third (33%) of the men reported receptive UAI with
ejaculation, 14% reported receptive UAI with withdrawal
and 16% insertive UAI only (strategic positioning).
Number of casual partners
Thirty-seven percent of men reported ten or more
casual sexual partners in the last six months,
Circumcision status
A third (34%) of the men reported being uncircumcised.
STIs
The prevalence of anal warts diagnoses made between
cohort study visits was 4% and the prevalence of anal
gonorrhoea diagnoses made at study visits was <1%.
Hazard ratios
Table 1 provides the hazard ratios for each factor consid-
ered in this study. A total of 53 HIV seroconversions were
observed during the follow-up period of the cohort with
an overall incidence rate of 0.78 per 100 person-years
(95%CI:0.59-1.02). The risk factor analysis was performed
on data associated with 47 HIV seroconverters for whom
sexual behaviour data were available within 12 months of
seroconversion.
UAI by reported HIV status of sexual partners
Compared to no UAI, UAI with any HIV-positive sexual
partners was significantly associated with 16.1 times the
risk of HIV seroconversion (95%CI:6.4-40.5); UAI with
unknown status sexual partners 4.4 times the risk of
HIV seroconversion (95%CI:1.8-11.2 and UAI with
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Page 4 of 10Figure 1 Diagram describing assumptions of time delays incorporated in costing calculations.
Table 1 Prevalence of risk factors and association between these risk factors and HIV seroconversion (hazard ratio)
Prevalence of behavior n (%)
(1) Number of HIV cases
(person-years)
Hazard ratio
(95% CI)
No UAI 521 (37) 7 (2071.4) 1
UAI by reported HIV status of sexual partners
(2)
UAI with HIV-negative only (serosorting) 466 (33) 14 (1958.7) 2.17 (0.88,5.39)
UAI with some unknown HIV status 362 (25) 13 (879.8) 4.44 (1.77,11.16)
UAI with any HIV-positive 77 (5) 13 (246.3) 16.12 (6.42,40.46)
UAI by sexual position
(2)
Insertive UAI only (strategic positioning) 225 (16) 4 (792.1) 1.54 (0.45,5.26)
Receptive with withdrawal (withdrawal) 204 (14) 11 (662.0) 5.00 (1.94,12.92)
Receptive with ejaculation 426 (33) 25 (1627.2) 4.65 (2.01,10.76)
Circumcision status
(3)
Uncircumcised men 488 (34) 17 (16.7) 1.22 (0.67,2.22)
Number of sexual partners
10+ casual sexual partners in the last 6 m 528 (37%) 20 (1370.8) 2.1 (1.12-3.74)
STIs
(4)
Anal warts between study visit 59 (4) 8 (197.1) 5.22 (2.44,11.18),
Anal gonorrhoea at study visit 4 (<1) 3 (42.8) 8.50 (2.60,27.95)
CI = Confidence interval, UAI = Unprotected anal intercourse, m = months.
1. Reported at baseline cohort asssessment.
2. Adapted from Jin et al [8].
3. Adapted from Templeton et al [9].
4. Adapted from Jin et al [21].
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conversion (95%CI:0.9-5.4) but this did not reach statistical
significance.
UAI by sexual position
Compared to no UAI, receptive UAI with ejaculation
was significantly associated with 4.7 times the risk of
HIV seroconversion (95%CI:2.0-10.8) and receptive UAI
with withdrawal 5.0 times the risk of HIV seroconver-
sion (95%CI:1.9-12.9). There was no significant
increased risk of HIV seroconversion associated with
insertive UAI only (strategic positioning).
Number of casual partners
Compared with less than ten partners, reporting ten or
more casual sexual partners in the last six months was
associated with 2.1 times the risk of HIV seroconversion
(95%CI:1.12-3.7).
Circumcision status
Compared to being circumcised, being uncircumcised
was not significantly associated with HIV seroconversion
(HR = 1.2, 95%CI:0.7-2.2).
STIs
Anal gonorrhoea was associated with 8.5 times the risk of
HIV seroconversion (95%CI:2.6-28.0) and anal warts 5.2
times the risk of HIV seroconversion (95%CI:2.4-11.2).
Population attributable risk
Tables 2 and 3 provide the PAR estimated for each fac-
tor included in multivariate model 1 and 2, respectively.
In model 1, the risk factors selected for the population
attributable risk analysis accounted for 91% (95%CI:81-
97%) of HIV seroconversions. In model 2, the risk
factors accounted for 94% (95%CI:82-98%) of HIV
seroconversions.
UAI by reported HIV status of sexual partners
In model 1, UAI with any HIV-positive partner accounted
for 34% (95%CI:24-44%) of HIV seroconversions, UAI
with some unknown HIV status men accounted for 33%
(95%CI:26-42%) of the HIV seroconversions and UAI with
HIV-negative partners accounted for 10% of the HIV sero-
conversions (95%CI:7-19%).
UAI by sexual position
In model 2, receptive UAI with ejaculation accounted
for 41% (95%CI:32-51%) of HIV seroconversions, recep-
tive UAI with withdrawal accounted for 28% (95%CI:20-
37%) of HIV seroconversions and insertive UAI only
(strategic positioning) 4% (95%CI:0.2-10%) of HIV
seroconversions.
Number of casual partners
Ten or more casual sexual partners in the past six months
accounted for 19% (95%CI:9-34%) of HIV seroconversions
in model 1 and 25% (95%CI:14-42%) in model 2.
Circumcision status
Being uncircumcised accounted for 7.0% of HIV sero-
conversions in model 1 and 2.
STIs
A study visit diagnosis of anal gonorrhoea was asso-
ciated with 2% of HIV seroconversions in model 1 and
2. An interval diagnosis of anal warts was associated
with 13% of HIV seroconversions (95%CI:9-19%) in
model 1 and 12% (95%CI:8-18%) in model 2.
HIV costs
Tables 2 and 3 also provide the average lifetime health-
care costs incurred from HIV seroconversions associated
with specific risk factors in multivariate model 1 and 2,
respectively.
UAI by reported HIV status of sexual partners
In model 1, UAI with any HIV-positive sexual partners
led to an average lifetime incurred health care cost of
$AUD102 million for the estimated 238 new infections
each year associated with this risk behaviour (range:
$AUD93 to $114 million) (3% discounting). UAI with
some unknown HIV status sexual partners also led to a
similar average lifetime incurred cost of $AUD99 million
(range: $AUD99-110 million) and serosorting led to an
average lifetime incurred cost of $AUD30 million
(range: $AUD27 to $33 million) (Table 3).
UAI by sexual position
In model 2, receptive UAI with ejaculation led to an
average lifetime incurred cost of $AUD123 million for
the estimated 287 new infections each year associated
with this risk behaviour (range: $AUD112 to $137 mil-
lion), receptive UAI with withdrawal led to an average
incurred cost of $AUD84 million (range: $AUD77 to
$94 million), and insertive UAI only (strategic position-
ing) $AUD12 million (range: $AUD11 to $13 million).
Number of casual partners
Ten or more casual sexual partners in the past six
months led to an average incurred health care cost of
$AUD57 million for the estimated 133 new infections
each year associated with this risk behaviour (range:
$AUD52 to $64 million) in model 1. In model 2, the
costs increased to $AUD75 million (range: $AUD68 to
$84 million).
Circumcision status
Being uncircumcised led to an average incurred health care
cost of $AUD21 million for the estimated 49 new infec-
tions each year associated with this risk (range: $AUD19 to
$23 million) in model 1. In model 2 costs were similar:
$AUD21 million (range: $AUD19 to $23 million).
STIs
In model 1 and 2, anal gonorrhoea led to an average
incurred cost of $AUD6 million for the estimated 14
new infections each year associated with this risk factor,
ranging from $AUD5 to $7. In model 1, anal warts led
to an average incurred cost of $AUD39 million (range:
$AUD36 to $43 million) and $AUD 36 million (range:
$AUD 33 to 40 million) in model 2.
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To our knowledge this study is the first attempt to
investigate the PAR of HIV risk factors, and at the same
time estimate the costs incurred as a result of these spe-
cific risk factors. The PAR represents an estimate of the
proportion of infections eliminated, taking account of
relationships with other variables. We found that UAI
with any HIV-positive sexual partners was reported
by 5% of men, the hazard ratio (HR) was 16.1 (95%
CI:6.4-40.5), the PAR was 34% (95%CI:24-44%) and the
average incurred healthcare costs was $102 million for
the new infections each year associated with this risk
factor. UAI with sexual partners of unknown HIV status
was reported by 25% of men, the HR was 4.4 (95%
CI:1.8-11.2), the PAR was 33% (95%CI:26-42%) and the
incurred costs were $99 million. The prevalence of anal
warts was 4%, the HR was 5.2 (95%CI:2.4-11.2), the PAR
was 13% (95%CI:9-19%) and the incurred costs were $39
million for infections attributable to this risk factor each
year.
The use of PAR allows us to estimate the numbers of
infections in the populationa s s o c i a t e dw i t hs p e c i f i c
behavioural practices and partner choice strategies. This
information should assist in identifying how to optimally
target health promotion activities. In practice, it is
unlikely that the total elimination of a particular beha-
viour or partner choice strategy can be achieved by
health promotion and some replacement behaviour may
occur. Furthermore, strategie sm a yh a v ed i f f e r e n tc o s t s
per unit of impact. Therefore the findings of the PAR
analysis should be viewed as one element in making
decisions about health promotion strategies.
We found that although UAI with any HIV-positive
sexual partner was a relatively low-prevalence behaviour,
reported by 5% of men, it was associated with a 16-fold
greater risk of HIV than avoidance of UAI altogether. As
a result 34% of the population risk is attributable to this
behaviour, a similar proportion as was attributable to the
much more prevalent, but apparently less risky practice
of UAI with some unknown HIV status partners.
A previous study in the United States was able to deter-
mine that UAI with a partner of unknown HIV serostatus
was associated with a PAR of 15% and UAI with a HIV-
positive partner a PAR of 12%, however their PAR
method did not adjust for inter-relatedness (and hence
confounding) of the factors in the model [17].
Our analyses also demonstrated the population
impacts of risk reduction strategies on HIV transmis-
sion. Serosorting was associated with a much lower risk
than UAI with sexual partners of unknown or positive
Table 2 PAR of HIV seroconversion risk factors including UAI by HIV status of sexual partners
Risk factor PAR (95% CI)
Crude model
PAR (95% CI)
Adjusted
model
Average annual
number
of HIV cases
Average lifetime HIV costs
(range)
(1) AUD$million, 2010 dollars
1%
discounting
3%
discounting
5%
discounting
All risk factors - 0.91 (0.81,0.97) 637 434 (403-471) 274 (249-304) 180 (160-205)
UAI by HIV status of sexual
partners
(2)
0.85 (0.75,0.94) 0.77 (0.66,0.89) 539 367 (341-399) 232 (211-257) 152 (136-174)
UAI with HIV-negative only
(serosorting)
0.15 (0.11,0.22) 0.10 (0.07,0.19) 70 48 (44-52) 30 (27-33) 20 (18-23)
UAI with some unknown HIV status 0.34 (0.27,0.43) 0.33 (0.26,0.42) 231 157 (146-171) 99 (90-110) 65 (58-74)
UAI with any HIV-positive 0.36 (0.26,0.45) 0.34 (0.24,0.44) 238 162 (151-176) 102 (93-114) 67 (60-77)
Circumcision status
(3)
Uncircumcision 0.08 (0.04,0.16) 0.07 (0.03,0.14) 49 33 (31-36) 21 (19-23) 14 (12-16)
Number of sexual partners
10+ casual sexual partners in the
last 6 m
0.26 (0.18,0.36) 0.19 (0.09,0.34) 133 91 (84-98) 57 (52-64) 38 (33-43)
STIs
(4)
Anal warts between study visits 0.14 (0.10,0.18) 0.13 (0.09,0.19) 91 62 (58-67) 39 (36-43) 26 (23-29)
Anal gonorrhoea at study visit 0.06 (0.04,0.07) 0.02 (0.01,0.03) 14 10 (9-10) 6 (5-7) 4 (4-5)
CI = Confidence interval, PAR = population attributable risk, UAI = Unprotected anal intercourse, m = months.
1. The average healthcare costs incurred from HIV seroconversions associated with specific risk factors were calculated by multiplying the PAR percent for each
specific risk factor, by the 700 HIV infections associated with male homosexual exposure, by the average healthcare costs per HIV-infected person. We performed
sensitivity analyses by rate of discounting and according to the bounds in delays in durations of time between infection and diagnoses and commencement of
antiretroviral treatment but calculations were based on the best estimated PAR of the risk factors and not the 95% CI of the PAR.
2. Adapted from Jin et al [8].
3. Adapted from Templeton et al [9].
4. Adapted from Jin et al [21].
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Page 7 of 10HIV status. However because the strategy was practiced
by about a third of men it was associated with a PAR of
10%. Withdrawal was less commonly practiced (14% of
men) but was associated with a five-fold significantly
increased risk of HIV infection and thus a PAR of 28%.
This suggests that even though these risk reduction stra-
tegies can be associated with some success in containing
HIV at the population level they still account for a sub-
stantial number of HIV infections in the population. In
HIV-negative men, the effectiveness of serosorting as a
HIV prevention strategy will be compromised where
there is uncertainty about the HIV status of the sexual
partner. A study in Melbourne in 2008 demonstrated
that of 639 gay men recruited from community venues
31% of the 61 men with HIV infection were unaware of
their HIV-positive status. These men were highly sexu-
ally active, a third had never been tested for HIV before
and another third self-reported their previous HIV test
as being in the past six months [26].
We have developed a model that defines the PAR and
costs incurred as a result of specific risk factors. If a
health department is considering spending money on
reducing risk, it is now possible to estimate the overall
impact of the strategy on reducing HIV incidence. In our
study, the PAR associated with gonorrhea as a HIV risk
factor was 2% compared to 34% for UAI with any HIV-
positive partners. This means that strategies that aim to
eliminate gonorrhoea as a means of preventing HIV
infection would need to cost 17-fold less to be more
cost-effective (assuming that both strategies are equal in
terms of the proportion of the target population that they
are able to influence).
Our study has several limitations. First, participants in
the HIM cohort were not selected randomly and findings
may not be generalizable to the larger gay and homosexual
community. Second, behavioural data were obtained by
self-report and may be subject to recall and measurement
bias. For example, in seven HIV cases in the HIM cohort,
no UAI was reported. In some of these cases transmission
may have occurred through oral sex [27,28] or due to
transmission when a condom was used, but the risk of
HIV attributable to these behaviours exclusively has been
demonstrated to be very low[ 1 6 ] .B e c a u s et h e r ew e r e
seven HIV cases where no UAI was reported the overall
PAR will never reach 100%. Third, the definitions of risk
reduction behaviours were based on exclusive practice and
can only be generalised to those who applied the strategy
100% of the time. Fourth, men do not engage in a single
risk but cumulative risk events. Therefore a man’ss e r o -
conversion may not just be due one single risk factor but
Table 3 PAR of risk factors including UAI by sexual position
Risk factor PAR (95% CI)
Crude model
PAR (95% CI)
Adjusted
model
Average annual
number of HIV
cases
Average lifetime HIV costs
(range)
(1) AUD$million, 2010 dollars
1%
discounting
3%
discounting
5%
discounting
All risk factors 0.94 (0.82,0.98) 658 448 (416-487) 283 (257-314) 186 (165-212)
UAI by sexual position
(2) 0.78 (0.69,0.89) 0.73 (0.66,0.85) 511 348 (323-378) 220 (200-244) 144 (128-165)
Insertive UAI only (strategic
positioning)
0.12 (0.07,0.19) 0.04 (0.02,0.10) 28 19 (18-21) 12 (11-13) 8 (7-9)
Receptive UAI 0.66 (0.54,0.76) 0.69 (0.58,0.78) 483 329 (305-357) 208 (189-231) 136 (121-156)
Receptive with withdrawal 0.21 (0.16,0.28) 0.28 (0.20,0.37) 196 134 (124-145) 84 (77-94) 55 (49-63)
Receptive with ejaculation 0.45 (0.35,0.55) 0.41 (0.32,0.51) 287 196 (182-212) 123 (112-137) 81 (72-92)
Circumcision status
(3)
Uncircumcision 0.08 (0.04,0.16) 0.07 (0.03,0.15) 49 33 (31-36) 21 (19-23) 14 (12-16)
Number of sexual partners
10+ casual sexual partners in the
last 6 m
0.26 (0.18,0.36) 0.25 (0.14,0.42) 175 119 (111-129) 75 (68-84) 49 (44-56)
STIs
(4)
Anal warts between study visits 0.14 (0.10,0.18) 0.12 (0.08,0.18) 84 57 (53-62) 36 (33-40) 24 (21-27)
Anal gonorrhoea at study visit 0.06 (0.04,0.07) 0.02 (0.01,0.03) 14 10 (9-10) 6 (5-7) 4 (4-5)
CI = Confidence interval, PAR = population attributable risk, UAI = Unprotected anal intercourse, m = months.
1. The average healthcare costs incurred from HIV seroconversions associated with specific risk factors were calculated by multiplying the PAR percent for each
specific risk factor, by the 700 HIV infections associated with male homosexual exposure, by the average healthcare costs per HIV-infected person. We performed
sensitivity analyses by rate of discounting and according to the bounds in delays in durations of time between infection and diagnoses and commencement of
antiretroviral treatment but calculations were based on the best estimated PAR of the risk factors and not the 95% CI of the PAR.
2. Adapted from Jin et al [8].
3. Adapted from Templeton et al [9].
4. Adapted from Jin et al [21].
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Page 8 of 10multiple. Fourth, we did not separate UAI by partner type.
In fact, the most common form of receptive UAI is with a
regular partner who is known to be HIV-negative, and this
does not convey a significantly increased risk of HIV infec-
tion [8]. Fifth, we only included the broad category of cir-
cumcision as a variable, whereas Templeton and
colleagues found circumcision was associated with a sig-
nificantly reduced risk of infection in the minority of men
who expressed a preference for the insertive position dur-
ing anal intercourse [9]. We were unable to restrict our
P A Ra n a l y s i st om e nw i t hap r e f e r e n c ef o rt h ei n s e r t i v e
position as it limited the model to a small subset of the
HIV serconversions. Finally, we only focused on the costs
associated with HIV treatment and not other health care
costs or societal costs such as time off work due to hospi-
talisations, or costs incurred for individuals diagnosed
with HIV but not yet on HIV treatment.
Conclusion
In summary, our results indicate that over a third of
cases could be avoided by strategies focusing on elimi-
nating UAI with a HIV-positive partner and UAI with
any unknown HIV status partner. As anal warts are
caused by HPV subtypes which are vaccine-preventable,
a PAR of 13% of averted HIV infections should be fac-
tored into considering vaccination for young MSM. The
model demonstrates that the cost benefits of interven-
tions focused on specific risk factors may be substantial,
particularly when the benefits of prevention of a combi-
nation of risk factors are considered together. Our
results call for major efforts directed toward prevention
in subsets of the population at highest risk for HIV.
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